These analyses showed that (i) ABL1 had lower statistically significant levels (with log2 2−ΔΔCt < −1) in both androgen receptor-positive cell lines (22RV1 and LNCaP), but higher levels in the two androgen receptor-negative cell lines, although these values were not statistically significant; (ii) the EP300, FYN, MYC, PSMB2, and SRPK2 levels increased in all four prostate cancer cell lines, although the EP300 and FYN levels were not statistically significant. The gene discussed is SRPK2; the disease is prostate carcinoma.